Well given the design of the trial - one arm, open label - I highly doubt the results will settle much. Without a control wing, it's just not possible to definitively say what part of the patients' treatment is effective. Hopefully MSB find it in their hearts to publish the full data including patient baselines so that a proper peer reviewed journal can have a good look.
After all, there's no better way to drive physician acceptance than a full dataset, properly peer reviewed unequivocally showing efficacy and safety.
- Forums
- ASX - By Stock
- MSB
- Back pain stem cell injection
MSB
mesoblast limited
Add to My Watchlist
2.90%
!
$2.34

Back pain stem cell injection, page-69
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$2.34 |
Change
-0.070(2.90%) |
Mkt cap ! $3.084B |
Open | High | Low | Value | Volume |
$2.33 | $2.35 | $2.26 | $2.378M | 1.023M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 140 | $2.34 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$2.35 | 21549 | 6 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
10 | 15010 | 2.330 |
8 | 31492 | 2.320 |
11 | 33479 | 2.310 |
15 | 60810 | 2.300 |
6 | 11644 | 2.290 |
Price($) | Vol. | No. |
---|---|---|
2.340 | 516 | 2 |
2.350 | 23813 | 9 |
2.360 | 45890 | 10 |
2.370 | 28518 | 6 |
2.380 | 7851 | 4 |
Last trade - 10.04am 21/07/2025 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |